Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab
Philippe Sultanik, Claudia Campani, Edouard Larrey, Bertille Campion, Manon Evain, Charles Roux, Lorraine Blaise, Mathilde Wagner, Marika Rudler, Jean‐Charles Nault, Dominique Thabut, Manon Allaire
Topics & Concepts
MedicineInternal medicineAscitesDecompensationHepatocellular carcinomaGastroenterologyCohortCirrhosisRetrospective cohort studyPortal hypertensionEsophageal varicesProportional hazards modelBevacizumabSorafenibIncidence (geometry)Hazard ratioConfidence intervalChemotherapyOpticsPhysicsHepatocellular Carcinoma Treatment and PrognosisLiver Disease and TransplantationLiver Disease Diagnosis and Treatment